Home
Upcoming Webinars Archived Webinars eCongress About Xtalks Host A Webinar Contact Us Get Updates
E-mail
 photo facebookfollow_zpscb486e28.jpg
Register Today!

April 23, 2014

Using PK/PD Modeling for Antibody Drug Conjugate Translation

Speaker for this Event:
  • Dhaval Shah, PhD, MS Pharmaceutics, Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York
  • Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986. Since then, the pharmaceutical industry has sought opportunities to leverage antibody technology as therapeutic agents to treat human disease. PK/PD modeling has been a useful technique to integrate data generated from diverse test platforms in mechanism framework.

    This webinar will focus on :

  • An introduction and overview of Antibody Drug Conjugates
  • The development of a mechanistic PK/PD model for preclinical-to-clinical translation of ADCs
  • The application of PK/PD modeling, understanding the disposition of ADCs and a guide the development of ADCs
  • A live Q&A with the audience will follow the presentation.

    THIS PROGRAM IS INTENDED FOR:

    Scientists and laboratory manager involved with:

    • Antibody Drug Conjugates
    • Protein/Antibody Engineering
    • PK/PD
    • Pre-Clinical/Clinical R&D
    • PK/PD
    • Target Validation
    • Formulation
    • Oncology
    • CMC & Regulatory
    • QA/QC

    Register Today!

    ABOUT OUR SPEAKER:
     

    Dhaval Shah, PhD, MS Pharmaceutics, Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York


    Dr. Shah worked as a Prinicpal Scientist at Pfizer prior to his current position as Assistant Professor at UB, The State University of New York, his alma mater. Dr. Shah’s research interests include discovery and development of novel biological drugs like ADCs for the treatment of cancer, obesity. His work integrates the principles of PK/PD and mathematical modeling to quantify the efficacy and toxicity of drugs, which in turn provides a predictive systems framework for successful preclinical-to-clinical translation of drugs.

    Notable speaking engagements:

    Bench to Bedside Translation of ADC Efficacy, One Day Workshop at The New York Academy of Sciences held on Tuesday, January 28, 2014

    Employing PK/PD modeling and simulation to guide ADC development, Presentation at the 2013 World ADC Summit at San-Francisco

    Preclinical to Clinical Translation of Antibody Drug Conjugate (ADC) Efficacy using PK/PD Modeling and Simulation, AAPS Webinar on May 9, 2013

    Publications:

    Bench to bedside translation of Antibody Drug Conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

    On translation of Antibody Drug Conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

    Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

    Register Today!
     
    Copyright © 2014 Honeycomb Worldwide Inc.